Letter comments on a published article in the New England Journal of Medicine

Joseph M. Connors; John Radford

doi:10.1016/j.ejca.2018.09.020

Letter comments on a published article in the New England Journal of Medicine

Joseph M. Connors^*, John Radford

^*Corresponding author for this work

Division of Cancer Sciences (L5)

British Columbia Cancer Agency Branch

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	250-251
Number of pages	2
Journal	European Journal of Cancer
Volume	104
DOIs	https://doi.org/10.1016/j.ejca.2018.09.020
Publication status	Published - 23 Oct 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2018.09.020

Cite this

@article{4add7c49c03b4cd68101c1f37b237957,

title = "Letter comments on a published article in the New England Journal of Medicine",

author = "Connors, {Joseph M.} and John Radford",

note = "Funding Information: For both authors, the only potential conflict is that the study being discussed in the letter; ECHELON-1 trial was sponsored by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals (United States) and Seattle Genetics (United States). The sponsors reimbursed J.M.C.'s and J.R.'s institution for any costs associated with the conduct of the ECHELON-1 trial. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2018",

month = oct,

day = "23",

doi = "10.1016/j.ejca.2018.09.020",

language = "English",

volume = "104",

pages = "250--251",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Letter comments on a published article in the New England Journal of Medicine

AU - Connors, Joseph M.

AU - Radford, John

N1 - Funding Information: For both authors, the only potential conflict is that the study being discussed in the letter; ECHELON-1 trial was sponsored by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals (United States) and Seattle Genetics (United States). The sponsors reimbursed J.M.C.'s and J.R.'s institution for any costs associated with the conduct of the ECHELON-1 trial. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2018/10/23

Y1 - 2018/10/23

UR - http://www.scopus.com/inward/record.url?scp=85056609869&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.09.020

DO - 10.1016/j.ejca.2018.09.020

M3 - Letter

C2 - 30361101

AN - SCOPUS:85056609869

SN - 0959-8049

VL - 104

SP - 250

EP - 251

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Letter comments on a published article in the New England Journal of Medicine

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this